Total raised
$37.2M
Last: Series C 2020-10
Stage
Series C
Founded
2013
Headcount
14
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
Azura Ophthalmics is utilizing a deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of ophthalmic keratolytics to treat underserved ophthalmic conditions.
Azura has a robust clinical-stage program focused on resolving the pathophysiology of meibomian gland dysfunction and contact lens discomfort. It is Azura's belief that AZR-MD-001 can reverse the core pathophysiology of these conditions, alleviating their signs and symptoms.
Additional areas of focus include the development of the company's novel new chemical entities, which target the pathophysiology of ocular surface diseases with a multi-modal mechanism of action.
Funding history · 3 rounds · $37.2M total
2020-10
Series C
$20.0M
2017-10
Series B
$16.0M
2014-03
Series A
$1.2M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
medicationdrug-discoveryophthalmologychronic-patientsbiotechnologyeye-diseases